Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 and up

Functional Lung-Sparing Planning Guided by Lung Perfusion PET/CT vs. Anatomy for Lung SBRT

Official title: Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy

Run by University Hospital, Brest · NCT07289646 · Data updated 2026-11-12

We test whether planning lung SBRT with functional lung information from a PET/CT scan can spare healthy lung tissue and reduce side effects for adult patients with primary or metastatic lung tumors.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment418 (estimated)
SponsorUniversity Hospital, Brest
Academic / other
Drugs / interventionsradiation
Locations2 sites (Brest, Finistère and 1 other locations)
StatusRecruiting
StartedSeptember 4, 2026
Main results expectedJanuary 2030
Study endsJanuary 2030
Registry record updatedOctober 15, 2026
Trial IDNCT07289646 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults over 18 with planned SBRT for primary or metastatic lung tumors and without contraindications to the radiolabeled lung perfusion PET/CT procedure.

Probably not a fit

Patients with non-functional differences between planning methods or those unlikely to benefit from regional functional sparing may not experience improved outcomes.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 3 trial compares two planning approaches for lung SBRT. One uses conventional anatomical planning, and the other uses functional lung avoidance planning based on 68Ga-MAA perfusion PET/CT to spare functioning lung regions. The goal is to reduce radiation-induced lung injury while maintaining tumor control. Eligible participants are adults planned for SBRT to primary or secondary lung tumors at participating centers. Outcomes focus on pulmonary toxicity, lung function, and treatment effectiveness.

Why it matters

Potential benefit: If successful, patients may experience lower risk of lung toxicity and better preservation of breathing function without sacrificing tumor control.

How similar studies have gone: Previous work in functional lung avoidance in radiotherapy shows promise, but this direct phase 3 comparison is relatively novel and aims to confirm benefit in a larger, diverse population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients aged \> 18 years planned to be treated in the radiotherapy department of the participating centers with SBRT for primary or secondary lung tumors will be eligible to participate into the study

Exclusion Criteria:

* Inability to give informed consent
* Patientsunder guardianship or curatorship
* Pregnant or breastfeeding women.
* Contraindications to the radiolabeled product infused for lung perfusion PET/CT.

Where it's running

  • CHU Brest
    Brest, Finistère, France
    Recruiting
  • Centre de Lutte Contre le Cancer Leon Bérard Lyon
    Lyon, France
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.